

What Urologists Want To Know: Addressing Current Questions and Controversies in the Management of Bladder Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- In the pivotal CheckMate-274 study, patients in which population experienced an improvement in disease-free survival with adjuvant nivolumab compared to placebo?**
 - Intention to treat only
 - PD-L1 $\geq 1\%$ only
 - Both a and b
- What was the overall response rate with enfortumab vedotin compared to chemotherapy in the EV-301 study for patients with previously treated advanced urothelial bladder cancer?**
 - More than double that of chemotherapy
 - Equivalent to chemotherapy
 - 10% better than chemotherapy
- To which of the following agents did the FDA grant accelerated approval, based on results from the Phase II TROPHY trial, for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor?**
 - Sacituzumab govitecan
 - Enfortumab vedotin
 - Erdafitinib
- Approximately what proportion of patients experienced central serous retinopathy in the BLC2001 study of erdafitinib for locally advanced or metastatic urothelial carcinoma?**
 - 25%
 - 10%
 - <5%